Cadila Pharmaceuticals

NGG advised Cadila Pharmaceuticals on entering the Australian market

Cadila Pharmaceuticals is a multinational research-based pharmaceutical group in India with over six decades of experience. The company’s integrated operations span the full range of products, including APIs, intermediates, finished formulations, OTC food supplements, biotechnology products, and pharmaceutical machinery. Its manufacturing facilities are approved by the world’s most stringent international bodies, including WHO-GMP, UK-MHRA, USFDA-API, TGA-Australia, and AIFA-Italy. Cadila’s global operations cover 58 countries, including the Americas, Japan, Asia, CIS, and Africa.

Cadila engaged NGG to explore strategic opportunities in the Australian market, including the supply of generic medicines, APIs, investment opportunities in Australian biotechnology, and pharmaceutical manufacturing in Australia.

India has a significant and rapidly growing presence in the global pharmaceutical industry, being the largest provider of generic medicines worldwide. It holds a 20% share in global supply by volume and supplies 50% of the world’s demand for vaccines. India is the source of 60,000 generic brands across 60 therapeutic categories and produces over 500 different APIs. India ranks third globally for production by volume and 13th by value, accounting for around 10% of the world’s production by volume and 1.5% by value.

NGG began by engaging with pre-qualified potential partners. A comprehensive market assessment was conducted to identify the best opportunities for Cadila. Three key companies were identified for private labelling of generic medicines, and five Australian biotech companies were shortlisted, from a list of 30, for potential investment in their intellectual property by Cadila’s scientists. NGG also prepared all necessary materials, showcasing Cadila’s historical performance and strong platform for pursuing growth opportunities.

Additionally, NGG identified an opportunity for Cadila to establish manufacturing in Australia. The company’s senior executives were introduced to one of the largest producers of vitamins and nutraceuticals, which was owned and managed by an Australian private equity firm.